EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Serotonin transporter SERT: a novel immune checkpoint for CD8 + T cell antitumor therapy

Qing Xiao, Xinchun Zhang, Xiaolong Liang, Gangfeng Yu, Yingrui Li, Ruoyang Du, Huiyu Xiang, Zailin Yang, Yao Liu

Journal for ImmunoTherapy of Cancer · 2026-02 · 14 (2) · e013294

DOI: 10.1136/jitc-2025-013294 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 24.02.2026. Verfasst von Qing Xiao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology-Oncology, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing U…. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Immunotherapy, Serotonin Plasma Membrane Transport Proteins, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: China Postdoctoral Science Foundation, Chongqing Shapingba District Technology Innovation Project, National Natural Science Foundation of China Youth Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This Highlight describes a key observation where serotonin transporter (SERT) was shown to suppress CD8 + T cell antitumor responses via depletion of intratumoral 5-HT. While selective serotonin reuptake inhibitors (SSRIs)—among the most widely used antidepressants—significantly inhibit tumor growth and enhance T cell-mediated antitumor immunity in both mouse models and human xenografts, showing remarkable synergy with anti-PD-1 therapy. These findings emphasize the importance of intratumoral 5-HT signaling, establish SERT as an immune checkpoint, and identify SSRIs as promising candidates for cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD8-Positive T-LymphocytesImmunotherapySerotonin Plasma Membrane Transport ProteinsNeoplasmsImmune Checkpoint InhibitorsHumansAnimalsMice

Stichwörter der Autor:innen

Immune Checkpoint InhibitorImmunotherapyT cell

Substanzen

Serotonin Plasma Membrane Transport ProteinsImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Hematology-Oncology, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, China.
  • Department of Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing Medical University, Chongqing, China.
  • Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Department of Cardiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China.
  • Department of Urology, Chongqing Emergency Medical Center, Chongqing University Central Hospital, Chongqing, China.
  • Department of Hematology-Oncology, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, China liuyao77@cqu.edu.cn zailin…

Förderung

  • China Postdoctoral Science Foundation
  • Chongqing Shapingba District Technology Innovation Project
  • National Natural Science Foundation of China Youth Project

Zitieren

APA

Xiao, Q., Zhang, X., Liang, X., Yu, G., Li, Y., Du, R., Xiang, H., Yang, Z., & Liu, Y. (2026). Serotonin transporter SERT: a novel immune checkpoint for CD8 + T cell antitumor therapy. Journal for ImmunoTherapy of Cancer, 14(2), e013294. https://doi.org/10.1136/jitc-2025-013294

Vancouver

Xiao Q, Zhang X, Liang X, Yu G, Li Y, Du R, et al. Serotonin transporter SERT: a novel immune checkpoint for CD8 + T cell antitumor therapy. Journal for ImmunoTherapy of Cancer. 2026;14(2):e013294. doi:10.1136/jitc-2025-013294

BibTeX
@article{Xiao2026,
  author = {Xiao, Qing and Zhang, Xinchun and Liang, Xiaolong and Yu, Gangfeng and Li, Yingrui and Du, Ruoyang and Xiang, Huiyu and Yang, Zailin and Liu, Yao},
  title = {Serotonin transporter SERT: a novel immune checkpoint for CD8 + T cell antitumor therapy},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  volume = {14},
  number = {2},
  pages = {e013294},
  doi = {10.1136/jitc-2025-013294}
}
Kostenlos starten →